Clinical Trial

A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 10, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to assess the safety and tolerability of GIGA-564 and identify the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) level(s) of GIGA-564 in participants with metastatic or locally advanced solid tumor malignancies.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2024-02-06; most recent amendment 2025-04-09.
Status change: Not Yet Recruiting → Recruiting 2024-04-08
Trial Details
NCT Number NCT06258304
Lead Sponsor GigaGen, Inc.
Collaborators: National Cancer Institute (NCI)
Conditions Advanced or Metastatic Solid Tumor Malignancies
Enrollment 60 participants
Start Date 2024-05-08
Primary Completion 2026-04 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2025-04-10